Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 559-565

  Ferolla, Silvia Marinho ^a   De Almeida Armiliato, Geyza Nogueira ^a   Couto, Cláudia Alves ^a   Ferrari, Teresa Cristina Abreu ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Fatty liver; Intestinal microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Probiotic

Indexed keywords

EID: 84928940969     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.559     Document Type: Article

References (34)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
2. Rozman D. From nonalcoholic Fatty liver disease to hepatocellular carcinoma: a systems understanding. Dig Dis Sci 2014; 59: 238-241 [PMID: 24385011 DOI: 10.1007/s10620-013-2998-x]
3. Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? Am J Gastroenterol 2011; 106: 78-80 [PMID: 21212755 DOI: 10.1038/ ajg.2010.310]
4. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18:1220-1221 [DOI: 10.1046/j.1440-1746.2003.03156.x]
5. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019 [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030]
6. Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012; 56: 1311-1318 [PMID: 22532269 DOI: 10.1002/hep.25805]
7. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during oneyear metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol 2012; 11: 61 [PMID:22676459 DOI: 10.1186/1475-2840-11-61]
8. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56: 1291-1299 [PMID: 22505276 DOI: 10.1002/hep.25778]
9. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-678 [PMID: 12406438 DOI: 10.1053/ bega.2002.0333]
10. Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31: S61-S66 [PMID:17331168 DOI: 10.1111/j.1530-0277.2006.00288.x]
11. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012; 46: 272-284 [PMID:22395062 DOI: 10.1097/MCG.0b013e31824587e0]
12. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, Cartenì M. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144-2146 [PMID: 12190198 DOI: 10.1111/j.1572-0241.2002.05942.x]
13. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]
14. Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008; 42: 1117-1119 [PMID: 18936646 DOI: 10.1097/MCG.0b013e31816d920c]
15. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
16. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-1095 [PMID: 22013734]
17. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57:545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
18. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-262 [PMID:23396737]
19. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014; 99: 535-542 [PMID: 24401715 DOI:10.3945/ajcn.113.068890]
20. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011; 22:699-711 [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002]
21. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911]
22. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.e1; quiz e60 [PMID:21440669 DOI: 10.1016/j.cgh.2011.03.020]
23. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253 [PMID: 21726509 DOI:10.1053/j.gastro.2011.06.061]
24. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609 [PMID: 23055155 DOI:10.1002/hep.26093]
25. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004; 12: 562-568 [PMID: 15539116 DOI: 10.1016/j.tim.2004.10.008]
26. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53: 606-613 [PMID: 20101384 DOI: 10.1007/s00125-010-1662-7]
27. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI:10.1002/hep.22848]
28. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642 [PMID: 15747110 DOI: 10.1007/s00125-005-1682-x]
29. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028 [PMID: 12107194 DOI: 10.1210/jcem.87.7.8638]
30. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42:987-1000 [PMID: 16250043 DOI: 10.1002/hep.20920]
31. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969 [PMID: 19585655 DOI: 10.1002/hep.23046]
32. Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm 2013; 2013: 986734 [PMID: 23840101 DOI: 10.1155/2013/986734]
33. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723 [PMID: 15505215 DOI: 10.1073/ pnas.0407076101]
34. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology:human gut microbes associated with obesity. Nature 2006; 444:1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]